NBIX Stock: Price, Earnings History and SEC Filings
Neurocrine Biosciences, Inc. (NBIX) last traded at $146.10, down 0.19% on the latest session and up 3.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $2.36 against an analyst estimate of $1.88, a beat of 25.5%.
$146.10 -0.19%
1 month+3.00%
52-week high$186.12
52-week low$122.14
Volume1.32M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NBIX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $2.36 | $1.88 | +25.53% |
| Mar 2026 | May 5, 2026 | $1.41 | $1.28 | +10.16% |
| Dec 2025 | Feb 11, 2026 | $1.43 | $1.78 | -19.66% |
| Sep 2025 | Oct 28, 2025 | $2.04 | $1.58 | +29.11% |
NBIX beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for NBIX
SEC filing data is not available right now. You can search for NBIX on SEC EDGAR.
NBIX news
- Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal HyperplasiaOct 30, 2026 · finance.yahoo.com
- Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter 2026Oct 30, 2026 · finance.yahoo.com
- Here's why Neurocrine Biosciences (NBIX) is a strong growth stockOct 30, 2026 · msn.com
- Neurocrine Biosciences stock: Q3 results set for November 2Oct 29, 2026 · ad-hoc-news.de
- Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?Oct 29, 2026 · finance.yahoo.com
- Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?Oct 27, 2026 · finance.yahoo.com
- Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?Oct 26, 2026 · finance.yahoo.com
- Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive DyskinesiaOct 26, 2026 · finance.yahoo.com
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (NBIX) is a US-listed public company on Nasdaq.